by Katie Davis
Posted in Biopharma, Life Science & Diagnostics
Across the life sciences market, IPOs are more than just fundraising —they are indicators of investor confidence and market potential. After a slowdown in recent years, IPO activity is picking up pace again in 2025, particularly within biotech. In this blog, Katie Davis explores the latest IPO trends, the companies shaping the market, and the key takeaways for those looking to capitalize on this evolving landscape.